Displaying 1–10 of 489 results
Oct 24, 2020 EDT Event
Participants from across the nation will join together virtually on October 24th to show our united, unwavering commitment to the Foundation Fighting Blindness’ mission to search for treatments and cures for blinding retinal diseases.
Aug 20, 2020 EDT Event
Aug 5, 2020 The Foundation in the News
In 2018, the Foundation Fighting Blindness launched a venture philanthropy investment arm called the Retinal Degeneration (RD) Fund to help companies and researchers advance promising treatments for inherited retinal diseases into and through early-stage human studies. Currently, the RD Fund has allocated about 75% of its $72 million fund to eight investments.
Aug 4, 2020 Eye On the Cure Research News
Gene therapy delivered by intravitreal injection
Aug 4, 2020 Foundation News
The Foundation Fighting Blindness is pleased to provide an audio recording and full transcripts of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on July 30, 2020.
Aug 3, 2020 Beacon Stories
Award-nominated recording artist Lachi has collaborated with some of the biggest names in the industry with millions of streams on her music. But with all her many amazing musical accomplishments, it wasn’t until a few years ago that she fully embraced herself as a legally blind artist who identifies with the disability community as closely as she does with music.
Aug 3, 2020 Eye On the Cure Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
Jul 30, 2020 Eye On the Cure Research News
University of Pennsylvania investigators studied retinas of patients and canines with retinitis pigmentosa caused by mild mutations in RHO
Jul 29, 2020 The Foundation in the News
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
Jul 27, 2020 Eye On the Cure Research News
The emerging therapy is designed to work independent of the mutated gene causing vision loss